Gastrointestinal Stromal Tumors Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
See the next evidence inflection points before they arrive. This readout-outlook report connects Clinical Trials, Drug & Asset, and Company & Deal Intelligence data through PatSnap MCP Servers. Explore the PatSnap MCP Marketplace to monitor the same endpoint, sponsor and timing signals inside your own AI workflow.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. This is strategic research, not medical advice. Trial status, endpoints and timing can change; confirm the underlying records before making decisions.
Readout outlook: why this landscape matters now
Gastrointestinal Stromal Tumors remains an active clinical development field. The competitive center of gravity is moving toward biomarker-defined populations, rational combinations, earlier treatment lines and evidence that can survive active-comparator scrutiny. The PatSnap evidence set used here contains 260 matched trial records and 546 indexed result records before the decision-focused sample below was selected. This companion outlook shifts the decision lens from market breadth to evidence timing: which endpoints can change practice, which sponsors can execute across geographies, and where the next readout may still leave uncertainty.
MCP workflow for a readout-focused landscape
The analysis starts with Clinical Trials MCP and clinical_trial_fetch to align phase, recruitment status, sponsor, countries, primary endpoints and completion dates. clinical_trial_result_fetch then separates already indexed evidence from future catalysts. Drug & Asset drug_fetch adds mechanism and global development status; Company & Deal Intelligence organization_fetch adds sponsor context. Use PatSnap MCP Servers to keep each layer traceable instead of inferring asset or company facts from trial titles.
Trial, endpoint and expected-readout map
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07700758 | Belzutifan | Phase 2; Not yet recruiting | Merck Sharp & Dohme LLC | Geography not listed | Number of Participants Who Experience One or More Adverse Events (AEs) (Up to approximately 5 years); Number of Participants Who Discontinue Study Intervention Due to an AE (Up to approximately 5 years) | 2034-01-02 |
| JPRN-jRCT1030260304 | Intervention not normalized | Phase 3; 募集中 | Ethicon, Inc. | Japan | 術後12カ月時点における腹壁瘢痕ヘルニアの発生割合; Incidence of incisional abdominal wall hernia at 12 months postoperatively | 2030-11-30 |
| NCT07697248 | Intervention not normalized | Not Applicable; Recruiting | Life Raft Group, Inc. | United States | Overall survival (From the date of registry enrollment until death from any cause, assessed…); Progression Free Survival (From the date of registry enrollment until the first documented disease…) | 2099-12-31 |
| NCT07689201 | Velzatinib | Phase 2; Not yet recruiting | GSK Plc | Geography not listed | Confirmed objective response rate (ORR) (Up to 67 weeks) | 2027-12-13 |
Read the table horizontally. Phase shows nominal maturity, but endpoint choice shows what the study can actually prove; geography signals operational breadth; and expected timing reveals whether a program is a near-term catalyst or a long-duration strategic bet.
Readout signals already on record
- StrateGIST 3: A randomized, phase 3 study of velzatinib (IDRX-42) versus sunitinib in patients with advanced gastrointestinal stromal tumors after imatinib therapy. (Phase 3): the indexed record reports ORR(2nd-line) = 33.0 % ( 19.5 - 48.0).
- Standard-dose ripretinib plus sunitinib versus ripretinib dose escalation in advanced GIST after progression on four prior therapies: Preliminary results of a multicenter cohort study. (Not Applicable): the indexed record reports AE(grade ≥3) = no grade ≥3 adverse events reported; AE(grade ≥3) = no grade ≥3 adverse events reported.
- Ripretinib as preoperative therapy in patients with potentially resectable advanced gastrointestinal stromal tumors after imatinib failure: Final analysis of a prospective, multicenter study. (Phase 2): the indexed record reports NED Rate = 92.9 %.
These signals are anchors, not league tables. Differences in population, prior treatment, baseline risk, estimand, endpoint definition and follow-up can overwhelm apparent numerical comparisons. The useful question is which uncertainty each result resolves before the next catalyst.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
How assets and sponsors shape readout probability
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Belzutifan (Approved; HIF-2α), Velzatinib (Phase 3; TYK2 x c-Kit). Company & Deal Intelligence records identify sponsor context for Merck Sharp & Dohme LLC, Ethicon, Inc., Life Raft Group, Inc., GSK Plc (GSK). Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Evidence white space before the next readout cycle
- Prospective biomarker thresholds that predict benefit rather than simply confirm target presence.
- Randomized sequencing evidence after prior targeted therapy, immunotherapy or antibody–drug conjugates.
- Endpoints that connect response depth with durability, quality of life and overall survival.
- Geographically broader development programs with harmonized molecular testing.
Readout-risk implications
A crowded field does not guarantee a crowded evidence set. Programs can still differentiate through an active comparator, a clinically meaningful endpoint, a biomarker-defined responder group, broader geography, or a credible sequencing plan. Sponsors should pressure-test whether the planned readout will close a decision gap; BD teams should distinguish mechanism novelty from evidence novelty; investors should track endpoint maturity and execution risk alongside phase.
Readout watchlist
Monitor recruitment changes, protocol amendments, primary-completion dates, new result indexing, sponsor ownership and multinational expansion. Re-run the MCP workflow as a delta analysis. A change from surrogate to clinical outcome, a delayed completion date, a new active comparator or a scaled partner can materially alter the probability and strategic meaning of the next readout.
Bottom line
Gastrointestinal Stromal Tumors has multiple clinical catalysts, but their value depends on endpoint quality, execution and context. A readout outlook is most useful when it joins trial design, indexed results, asset mechanism and sponsor capacity in one traceable view.
Build your own readout monitor: Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable components for catalyst tracking and SEO-ready reports.
